These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38509334)

  • 21. Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis.
    Niegisch G; Grimm MO; Hardtstock F; Krieger J; Starry A; Osowski U; Guenther S; Deiters B; Maywald U; Wilke T; Kearney M
    Future Oncol; 2024; 20(19):1351-1366. PubMed ID: 38647011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel therapeutic targets in advanced urothelial carcinoma.
    Rouanne M; Loriot Y; Lebret T; Soria JC
    Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary management of stage T1 transitional cell carcinoma of the bladder.
    Sataa S; Yassine N; Ghassen HH; Imed BS; Mohamed C; Maher C; Ali H
    Tunis Med; 2005 Dec; 83 Suppl 12():87-9. PubMed ID: 16430077
    [No Abstract]   [Full Text] [Related]  

  • 24. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Tilgener C; Bedke J
    Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421
    [No Abstract]   [Full Text] [Related]  

  • 25. M-VAC chemotherapy in the management of locally advanced bladder cancer.
    Skinner DG
    J Urol; 1988 Mar; 139(3):570. PubMed ID: 3343745
    [No Abstract]   [Full Text] [Related]  

  • 26. The landscape of immunotherapy in metastatic urothelial carcinoma.
    Teo MY; Iyer G
    Curr Opin Urol; 2019 Nov; 29(6):643-648. PubMed ID: 31567441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combination chemotherapy with cisplatin and methotrexate in advanced bladder cancer].
    Kobayashi K; Komatsu H; Takihana Y; Shirasu N; Tanabe N; Ishihama T; Takei K; Yamada Y; Ueno A
    Nihon Hinyokika Gakkai Zasshi; 1986 Jul; 77(7):1182-7. PubMed ID: 3784207
    [No Abstract]   [Full Text] [Related]  

  • 28. Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?
    Sonpavde G; Bellmunt J
    Oncologist; 2015 May; 20(5):461-3. PubMed ID: 25845991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Editorial Comment on "Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey".
    Giudice GC; Sonpavde GP
    Int J Urol; 2024 Aug; 31(8):943-944. PubMed ID: 38825971
    [No Abstract]   [Full Text] [Related]  

  • 30. [Systemic chemotherapy for transitional cell carcinoma of the urothelium].
    Lehmann J; Retz M; Hack M; Siemer S; Stöckle M
    Onkologie; 2003 Oct; 26 Suppl 4():18-25. PubMed ID: 14605452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation criteria: a protocol to study patterns of care and their effects in patients with transitional cell carcinoma of the bladder (protocol 1).
    Prout GR; Kopp J
    Prog Clin Biol Res; 1984; 162A():285-99. PubMed ID: 6483913
    [No Abstract]   [Full Text] [Related]  

  • 32. Importance of node dissection in relation to neoadjuvant and adjuvant therapy.
    Huang WC; Bochner BH
    J Natl Compr Canc Netw; 2006 Nov; 4(10):1019-26. PubMed ID: 17112450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New concepts in the management of MIBC in 2010].
    Pignot G; Molinié V; Coloby P; Culine S; Gravis G; Rossi D; Theodore C; Zerbib M
    Prog Urol; 2011 Mar; 21 Suppl 2():S38-42. PubMed ID: 21397826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preoperative or neoadjuvant chemotherapy. Our experience with 37 patients].
    Escudero Barrilero A; Fernández E; Crespo C
    Arch Esp Urol; 1991 May; 44(4):379-92. PubMed ID: 2064440
    [No Abstract]   [Full Text] [Related]  

  • 35. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen.
    Sternberg CN; Yagoda A; Scher HI
    Prog Clin Biol Res; 1988; 277():45-51. PubMed ID: 3054909
    [No Abstract]   [Full Text] [Related]  

  • 36. Second-line treatment of advanced transitional cell carcinoma of the urothelial tract.
    Sternberg CN
    Curr Opin Urol; 2001 Sep; 11(5):523-9. PubMed ID: 11493775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
    Taguchi S; Kawai T; Nakagawa T; Kume H
    BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
    [No Abstract]   [Full Text] [Related]  

  • 38. Letter to the editor for the article "Molecular urothelial tumor cell subtypes remain stable during metastatic evolution".
    Song Y; Peng Y; Xu T
    World J Urol; 2023 Oct; 41(10):2869-2870. PubMed ID: 37516671
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer.
    Giridhar KV; Kohli M
    Mayo Clin Proc; 2017 Oct; 92(10):1564-1582. PubMed ID: 28982487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Organ conservation in deeply invasive bladder cancer.
    Fair WR
    Prog Clin Biol Res; 1991; 370():119-26. PubMed ID: 1924440
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.